MEP20608A - Immune response modifier sterile formulations and methods - Google Patents

Immune response modifier sterile formulations and methods

Info

Publication number
MEP20608A
MEP20608A MEP-206/08A MEP20608A MEP20608A ME P20608 A MEP20608 A ME P20608A ME P20608 A MEP20608 A ME P20608A ME P20608 A MEP20608 A ME P20608A
Authority
ME
Montenegro
Prior art keywords
methods
immune response
response modifier
imidazo
sterile formulations
Prior art date
Application number
MEP-206/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
James D Stoesz
Alexis S Statham
Myhanh T Truong
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP20608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of MEP20608A publication Critical patent/MEP20608A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MEP-206/08A 2006-07-31 2007-07-17 Immune response modifier sterile formulations and methods MEP20608A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82087606P 2006-07-31 2006-07-31

Publications (1)

Publication Number Publication Date
MEP20608A true MEP20608A (en) 2010-06-10

Family

ID=38617896

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-206/08A MEP20608A (en) 2006-07-31 2007-07-17 Immune response modifier sterile formulations and methods

Country Status (24)

Country Link
US (1) US8124096B2 (es)
EP (1) EP1891953B1 (es)
AR (1) AR062121A1 (es)
AT (1) ATE532511T1 (es)
AU (1) AU2007279376B2 (es)
CA (1) CA2659733A1 (es)
CL (1) CL2007002228A1 (es)
CY (1) CY1112264T1 (es)
DK (1) DK1891953T3 (es)
ES (1) ES2375744T3 (es)
HR (1) HRP20120128T1 (es)
IL (1) IL184652A (es)
ME (1) MEP20608A (es)
NO (1) NO338958B1 (es)
PE (1) PE20080523A1 (es)
PL (1) PL1891953T3 (es)
PT (1) PT1891953E (es)
RS (2) RS52120B (es)
RU (1) RU2474425C2 (es)
SI (1) SI1891953T1 (es)
UA (1) UA93496C2 (es)
UY (1) UY30513A1 (es)
WO (1) WO2008016475A2 (es)
ZA (1) ZA200900618B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
NZ545412A (en) * 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
BRPI0414867A (pt) 2003-10-03 2006-11-21 3M Innovative Properties Co pirazolopiridinas e seus análogos
BRPI0414856A (pt) 2003-10-03 2006-11-21 3M Innovative Properties Co imidazoquinolinas alcóxi-substituìdas
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1831226B1 (en) * 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
ES2475728T3 (es) 2005-02-09 2014-07-11 3M Innovative Properties Company Tiazoloquinolinas y tiazolonaftiridinas sustituidas con alcoxi
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1850849A2 (en) * 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008543725A (ja) * 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
JP2008531567A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
SI2378876T1 (sl) 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
PT2606047T (pt) 2010-08-17 2017-04-07 3M Innovative Properties Co Composições, formulações e métodos de um composto lipidado modificador da resposta imunitária
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
LU92856B1 (en) 2014-02-21 2016-02-21 Avadim Technologies Inc Method for maintenance of urethral catheters
US20160158393A1 (en) * 2014-02-21 2016-06-09 Avadim Technologies, Inc. Method for Improving Health Outcomes
JP2017534689A (ja) 2014-11-19 2017-11-24 アヴァディム・テクノロジーズ，インコーポレイテッド ざ瘡の予防および治療のための方法
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24906A (en) * 1859-07-26 Simeon goodfellow
IT610737A (es) 1955-11-18 1900-01-01
US3700674A (en) * 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) * 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) * 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4197403A (en) * 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4191767A (en) * 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
DE3364438D1 (en) 1982-10-18 1986-08-14 Pfizer Triazoloquinoxalines as antidepressants and antifatigue agents
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
EP0187705A3 (en) 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
EP0375689B1 (en) 1987-06-01 1992-08-12 Warner-Lambert Company A pharmaceutical composition adapted for transdermal delivery of an opoid drug.
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
CA2104782C (en) 1991-03-01 2001-08-07 John F. Gerster 1-substituted, 2-substituted 1h-imidazo-[4,5-c]quinolin-4- amines
WO1995002597A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
KR100518903B1 (ko) * 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0877089A1 (en) 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
DK1512685T3 (da) 1997-12-11 2006-11-20 Minnesota Mining & Mfg Imidazonaphthyridiner og deres anvendelse til induktion af cytokinbiosyntese
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (sk) * 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
RU2143900C1 (ru) * 1999-03-31 2000-01-10 Институт цитологии и генетики СО РАН Способ получения изониазида пролонгированного действия
DE19941509A1 (de) * 1999-08-31 2001-03-29 Interconnectron Ges Fuer Ind S Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen
US6464937B2 (en) * 2000-11-01 2002-10-15 Pml Microbiologicals, Inc. Ultrapure sterilization of microbiological test media by electron beam irradiation
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
PL210514B1 (pl) * 2001-11-29 2012-01-31 3M Innovative Properties Co Preparat farmaceutyczny zawierający modyfikator odpowiedzi immunologicznej
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
CA2536578A1 (en) 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1602365A1 (en) * 2004-03-03 2005-12-07 Switch Biotech Aktiengesellschaft Pharmaceutical composition for topical use in form of xerogels or films and methods for production
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine

Also Published As

Publication number Publication date
PL1891953T3 (pl) 2012-04-30
AR062121A1 (es) 2008-10-15
CA2659733A1 (en) 2008-02-07
PT1891953E (pt) 2012-01-24
RS52120B (en) 2012-08-31
US20100096287A1 (en) 2010-04-22
SI1891953T1 (sl) 2012-05-31
RS20070318A (en) 2009-05-06
ZA200900618B (en) 2010-03-31
CY1112264T1 (el) 2015-12-09
ES2375744T3 (es) 2012-03-05
IL184652A0 (en) 2008-01-20
WO2008016475A3 (en) 2008-11-20
IL184652A (en) 2014-02-27
UA93496C2 (uk) 2011-02-25
DK1891953T3 (da) 2012-02-27
AU2007279376B2 (en) 2012-09-06
ATE532511T1 (de) 2011-11-15
US8124096B2 (en) 2012-02-28
UY30513A1 (es) 2008-02-29
EP1891953B1 (en) 2011-11-09
PE20080523A1 (es) 2008-07-13
CL2007002228A1 (es) 2008-01-18
RU2007129104A (ru) 2009-02-10
AU2007279376A1 (en) 2008-02-07
NO20073913L (no) 2008-02-01
HRP20120128T1 (hr) 2012-03-31
WO2008016475A2 (en) 2008-02-07
NO338958B1 (no) 2016-11-07
EP1891953A1 (en) 2008-02-27
RU2474425C2 (ru) 2013-02-10

Similar Documents

Publication Publication Date Title
MEP20608A (en) Immune response modifier sterile formulations and methods
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
CY1118370T1 (el) 4-(8-μεθοξυ-1-((1-μεθοξυπροπαν-2-υλ)-2(τετραϋδρο-2η-πυραν-4-υλ)-1η-ιμιδαζο[4,5-c]κινολιν-7-υλ)-3,5-διμεθυλισοξαζολιο και χρηση αυτου ως αναστολεας βρωμοπεδιο
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
PE20100469A1 (es) Formulaciones de imiquimod
CL2015001973A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BRPI1012697A2 (pt) derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
NO20090610L (no) Faste preparater omfattende tadalafil og minst en baerer
GT200500287A (es) Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
TN2010000203A1 (en) Beta-lactamase inhibitors
UA101339C2 (ru) Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
EA201171363A1 (ru) Новые замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
NZ718163A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CR20120068A (es) Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales
WO2013192517A3 (en) Compounds for treating infectious diseases
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
EP2142549A4 (en) ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
BRPI0913297B8 (pt) composição farmacêutica estabilizada